Clinigen has acquired Cardioxane (dexrazoxane) from Novartis for $33m, which is payable in two tranches. As per the agreement, Clinigen will manufacture, register, distribute, and commercialize the product in countries where current ...
Tags: Clinigen, Cardioxane, Medicine
Clinigen Group and Theravance have signed an exclusive commercialization agreement for Vibativ (telavancin) in the EU and few other countries located in Europe. The bactericidal, once-daily injectable lipoglycopeptide antibacterial agent ...
The FDA has approved Clinigen Healthcare's supplemental new drug application (sNDA) for Foscavir (foscarnet sodium), a treatment for HIV/AIDS-related cytomegalovirus (CMV) infections and herpes. Hospira will distribute Foscavir to US ...